Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/34841
Title: Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: The safety profile of deferasirox
Authors: Ali T. Taher
John B. Porter
Vip Viprakasit
Antonis Kattamis
Suporn Chuncharunee
Pranee Sutcharitchan
Noppadol Siritanaratkul
Raffaella Origa
Zeynep Karakas
Dany Habr
Zewen Zhu
M. Domenica Cappellini
American University of Beirut
UCL
Mahidol University
University of Athens
King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University
Ospedale Regional Microcitemie
Istanbul Tip Fakultesi
Novartis Pharmaceuticals
Universita degli Studi di Milano
Keywords: Medicine
Issue Date: 1-Jan-2014
Citation: European Journal of Haematology. Vol.92, No.6 (2014), 521-526
Abstract: Objective: Patients with non-transfusion-dependent thalassemia (NTDT) often develop iron overload and related complications, and may require iron chelation. However, the risk of over-chelation emerges as patients reach low, near-normal body iron levels and dose adjustments may be needed. In the THALASSA study, the threshold for chelation interruption was LIC <3 mg Fe/g dw (LIC<3); 24 patients receiving deferasirox for up to 2 yr reached this target. A post hoc analysis was performed to characterize the safety profile of deferasirox as these patients approached LIC<3. Methods: THALASSA was a randomized, double-blind, placebo-controlled study of two deferasirox regimens (5 and 10 mg/kg/d) versus placebo in patients with NTDT. Patients randomized to deferasirox or placebo in the core could enter a 1-yr extension, with all patients receiving deferasirox (extension starting doses based on LIC at end-of-core and prior chelation response). The deferasirox safety profile was assessed between baseline and 6 months before reaching LIC<3 (Period 1), and the 6 months immediately before achieving LIC<3 (Period 2). Results: Mean ± SD deferasirox treatment duration up to reaching LIC<3 was 476 ± 207 d, and deferasirox dose was 9.7 ± 3.0 mg/kg/d. The exposure-adjusted AE incidence regardless of causality was similar in periods 1 (1.026) and 2 (1.012). There were no clinically relevant differences in renal and hepatic laboratory parameters measured close to the time of LIC<3 compared with measurements near the previous LIC assessment. Conclusions: The deferasirox safety profile remained consistent as patients approached the chelation interruption target, indicating that, with appropriate monitoring and dose adjustments in relation to iron load, low iron burdens may be reached with deferasirox with minimal risk of over-chelation. © 2014 The Authors. European Journal of Haematology Published by John Wiley & Sons Ltd.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84900489981&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/34841
ISSN: 16000609
09024441
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.